SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Acutaas Chemicals - Quaterly Results

18 Oct 2025 Evaluate
The sales figure stood at Rs. 3051.93 millions for the September 2025 quarter. The mentioned figure indicates a growth of about 25.29% as compared to Rs. 2435.92 millions during the year-ago period.Profit for the quarter ended September 2025 rises by 93.46% to Rs. 728.91  millions from Rs. 376.78 millions.Operating profit for the quarter ended September 2025 rose to 1055.75 millions as compared to 567.09 millions of corresponding quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 3051.93 2435.92 25.29 5111.64 4147.29 23.25 9898.35 6875.83 43.96
Other Income 89.70 85.78 4.57 249.90 104.75 138.57 183.36 137.86 33.00
PBIDT 1055.75 567.09 86.17 1725.84 849.05 103.27 2434.78 1214.53 100.47
Interest 5.72 4.94 15.79 11.92 48.67 -75.51 58.57 58.94 -0.63
PBDT 1050.03 562.15 86.79 1713.92 800.38 114.14 2376.21 838.05 183.54
Depreciation 77.22 61.96 24.63 151.84 118.17 28.49 240.45 146.94 63.64
PBT 972.81 500.19 94.49 1562.08 682.21 128.97 2135.76 691.11 209.03
TAX 243.90 123.41 97.63 386.71 168.26 129.83 540.29 254.25 112.50
Deferred Tax 50.38 4.89 930.27 65.91 13.56 386.06 70.58 45.12 56.43
PAT 728.91 376.78 93.46 1175.37 513.95 128.69 1595.47 436.86 265.21
Equity 409.36 409.28 0.02 409.36 409.28 0.02 409.34 368.81 10.99
PBIDTM(%) 34.59 23.28 48.59 33.76 20.47 64.92 24.60 17.66 39.26

Acutaas Chemicals Share Price

2415.40 4.25 (0.18%)
21-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1221.45
Cipla 1230.00
Zydus Lifesciences 930.90
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×